BRCA1 and breast cancer: Neoadjuvant chemotherapy with cisplatin has been applied in patients with BRCA1-associated breast cancer [13] and TNBC [14]; however, the outcomes of cisplatin-based neoadjuvant chemotherapy are heterogeneous.